United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

total potassium 7.5mmol/50ml) / disodium phosphate dihydrate 667.5mg solution for infusion 50ml pre-filled syringes (special order - potassium hydroxide; disodium phosphate dihydrate; potassium dihydrogen phosphate - solution for infusion - 1.4mg/1ml ; 13.35mg/1ml ; 17.01mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

total potassium 15mmol/500ml) / disodium phosphate dihydrate 1.335g infusion 500ml bags (special order - potassium hydroxide; disodium phosphate dihydrate; potassium dihydrogen phosphate - infusion - 280microgram/1ml ; 2.67mg/1ml ; 3.402mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

total potassium 30mmol/100ml) / disodium phosphate dihydrate 2.67g infusion 100ml bags (special order - potassium hydroxide; disodium phosphate dihydrate; potassium dihydrogen phosphate - infusion - 2.8mg/1ml ; 26.7mg/1ml ; 34.02mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; polysorbate 80; water for injections; glutamic acid; sorbitol - indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. ,indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. ,indicated for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies. ,indicated for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation.,in patients receiving myeloablative chemotherapy, is indicated for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation.,indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia.,indicated in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - filgrastim, quantity: 960 microgram/ml - injection, solution - excipient ingredients: sorbitol; polysorbate 80; sodium hydroxide; glutamic acid; water for injections - indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. ,indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. ,indicated for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies. ,indicated for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation.,in patients receiving myeloablative chemotherapy, is indicated for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation.,indicated for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia.,indicated in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

britannia pharmaceuticals ltd - apomorphine hydrochloride - solution for infusion - 5mg/1ml

Malta - English - Medicines Authority

bayer hellas s.a 6-8 agisilaou street 151 23 marousi attiki, , greece - gadoxetic acid, disodium - solution for injection in a pre-filled syringe - gadoxetic acid, disodium 0.25 mmol/ml - contrast media

Australia - English - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - etanercept, quantity: 50 mg - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate heptahydrate; sodium chloride; sucrose; water for injections - adults (18 years and older),rheumatoid arthritis,active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). brenzys can be used in combination with methotrexate. severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.,psoriatic arthritis,the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. etanercept has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.,plaque psoriasis,adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.,ankylosing spondylitis,the signs and symptoms of active ankylosing spondylitis in adults.,non-radiographic axial spondyloarthritis,treatment of adults with active* non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri change who have had an inadequate response to nsaids .,*active disease is defined as a bath ankylosing spondylitis disease activity index (basdai) score of greater than or equal to 4.

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - isoleucine; leucine ; lysine hydrochloride; methionine; phenylalanine; threonine; tryptophan; valine; arginine monoglutamate ; alanine; aspartic acid; glutamic acid ; glycine; proline; serine; magnesium acetate tetrahydrate; sodium acetate trihydrate ; sodium dihydrogen phosphate dihydrate; potassium hydroxide; sodium hydroxide ; glucose monohydrate; calcium chloride dihydrate; histidine hydrochloride monohydrate - solution for infusion - unknown - solutions for parenteral nutrition; combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - potassium dihydrogen phosphate; potassium hydroxide; disodium phosphate dihydrate - concentrate for solution for infusion - 170.1mg/ml+133.5mg/ml+14 milligram(s)/millilitre - electrolyte solutions; combinations of electrolytes